Table 2.
Adverse Events
| Adverse Event | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
| Dose Level 1: PAC-1 375 mg + TMZ 150 mg/m2 | ||||
| Hematologic | ||||
| Anemia | 3 | 0 | 0 | 0 |
| Leukopenia | 1 | 1 | 0 | 0 |
| Lymphopenia | 1 | 2 | 0 | 0 |
| Non-Hematologic | ||||
| Fatigue | 3 | 2 | 0 | 0 |
| Fever | 1 | 0 | 0 | 0 |
| Confusion | 1 | 0 | 0 | 0 |
| Somnolence | 0 | 1 | 0 | 0 |
| Neurologic, other | 3 | 0 | 0 | 0 |
| Concentration impairment | 1 | 0 | 0 | 0 |
| Dysgeusia | 1 | 0 | 0 | 0 |
| Bruising | 1 | 0 | 0 | 0 |
| Arthralgia | 1 | 0 | 0 | 0 |
| ALT increase | 0 | 0 | 1 | 0 |
| AST increase | ||||
| Dose Level 2: PAC-1 500 mg + TMZ 150 mg/m2 | ||||
| Non-Hematologic | ||||
| Cognitive disturbance | 0 | 1 | 0 | 0 |
| Headache | 0 | 1 | 0 | 0 |
| Paresthesia | 0 | 1 | 0 | 0 |
| Neurologic, other | 1 | 0 | 0 | 0 |
| Dose Level 3: PAC-1 625 mg + TMZ 150 mg/m2 | ||||
| Non-Hematologic | ||||
| Fatigue | 2 | 0 | 0 | 0 |
| Dizziness | 1 | 0 | 0 | 0 |
| Headache | 1 | 0 | 0 | 0 |
| Constipation | 1 | 0 | 0 | 0 |
| Diarrhea | 1 | 0 | 0 | 0 |